Goldman Sachs Downgrades Bristol-Myers Squibb (BMY) to Neutral, Likes Johnson & Johnson (JNJ) More

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/21/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. AVGO
7. SPCX
8. REAX
9. OSIS
10. RMAX

May 11, 2011 6:47 AM EDT
Get Alerts BMY Hot Sheet
Price: $67.01 +2.35%

Rating Summary:
    12 Buy, 22 Hold, 4 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Goldman Sachs downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Neutral, while upgrading Johnson & Johnson (NYSE: JNJ).

The firm said Bristol-Myers superior new product story is now better appreciated while Johnson & Johnson's remains under the radar screen.

Goldman said the downgrades does not imply a change in their constructive view on Bristol-Myers, but with less than 11% upside to their $32 price target they see better upside in Johnson & Johnson.

For more ratings news on Bristol-Myers Squibb Co. click here and for the rating history of Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $28.81 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Downgrades, Hot Downgrades

Related Entities

Goldman Sachs